Clinical trial
An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
NCT04561557 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Lead sponsor
- Tongji Hospital
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 22, 2020
- Completion date
- May 31, 2027
- Enrollment
- 36 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune diseases, autoimmune diseases of the nervous system, autoimmune encephalitis, chronic inflammatory demyelinating polyradiculoneuropathy, idiopathic inflammatory myopathies, multiple sclerosis, myasthenia gravis, myelin oligodendrocyte glycoprotein antibody-associated disease (mogad), neuromyelitis optica spectrum disorder, poems syndrome